Corcept Therapeutics Incorporated (CORT) support and resistance · P/E 199, rev $675.0M
Corcept Therapeutics Incorporated (CORT) is a biotechnology company listed on US.
This page maps Corcept Therapeutics Incorporated (CORT) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported CORT revenue for 2024-12-31 was $675.0M. Net income was $141.2M. Revenue was up 39.9% from 2023-12-31 to 2024-12-31. CORT currently screens at market cap $7.46B and trailing P/E 198.5.
CORT currently screens at market cap $7.46B and trailing P/E 198.5. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new CORT 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the CORT quote page for the session range and the stock page for the full model.
Not investment advice.